

Date: January 29, 2024

The Manager
BSE Limited (DCS- CRD)
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Scrip Code: 532039

Dear Sir,

Sub: Outcome of the Board Meeting of Zenotech Laboratories Limited (the Company) held today - Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2023

With reference to the intimation of Board Meeting submitted on January 17, 2024, we wish to inform you that the Meeting of the Board of Directors of the Company was held today i.e. January 29, 2024 which commenced at 5:00 p.m. IST and ended at 6:15 p.m. IST.

The Board has, *inter-alia*, approved and taken on record the Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2023.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Unaudited Standalone Financial Results of the Company for the quarter and nine months ended December 31, 2023 along with the Limited Review Report thereon issued by the Statutory Auditors of the Company.

We request you to take the same on your records.

Thanking you,

Yours faithfully,
For **Zenotech Laboratories Limited**

(Abdul Gafoor Mohammad)
Company Secretary & Compliance Officer
ICSI Membership No. A22331

Encl: as above

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

Independent Auditor's Review Report on review of Interim Financial Results

To the Board of Directors of Zenotech Laboratories Limited

1. We have reviewed the unaudited financial results ("the Statement") of **Zenotech Laboratories Limited** ("the Company") for the quarter and nine months ended 31st December 2023, being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

2. **Management's Responsibility**

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

3. **Auditor's Responsibility**

Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Jain Sadguru Images Capital Park, 6th Floor, Plot No: -1-98/4/1-12 28 & 29, Image Garden Road, Madhapur village, Serilingampally, Hyderabad-500081, Telangana Ph:040 29323743/29332743

Head Office/Registered Office • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai • 600004, India
Tel +91 44 28112985 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in

PKF SRIDHAR & SANTHANAM LLP is a registered limited liability partnership with LLPIN AAB-6552(Registration No. with ICAI is 003990S/S200018.

PKF SRIDHAR & SANTHANAM LLP

Chartered Accountants

4. Conclusion

Based on our review conducted, as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PKF Sridhar & Santhanam LLP

Chartered Accountants

Firm Registration No. 003990S/S200018

Viswanadh VNSS Kuchi
Viswanadh VNSS Kuchi


Partner

Membership No. 210789

Place: Hyderabad

Date: 29-January-2024

UDIN: 24210789BKGFEY2430



Jain Sadguru Images Capital Park, 6th Floor, Plot No: -1-98/4/1-12 28 & 29, Image Garden Road, Madhapur village, Serilingampally, Hyderabad-500081, Telangana Ph:040 29323743/29332743

Head Office/Registered Office • No.91-92 7th Floor • Dr.Radhakrishnan Salai • Mylapore • Chennai • 600004, India

Tel +91 44 28112985 • Fax +91 44 28112989 • Email sands@pkfindia.in • www.pkfindia.in

PKF SRIDHAR & SANTHANAM LLP is a registered limited liability partnership with LLPIN AAB-6552/Registration No. with ICAI is 003990S/S200018.

ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Statement of Standalone Unaudited Financial Results for the Quarter and Nine months ended 31 December 2023

(Rs in lakhs, except share and per equity share data)

Sl. No.	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	992.45	1,050.95	777.73	2,867.19	2,839.69	3,835.29
II	Other Operating Income	101.79	101.81	101.80	305.37	305.39	407.14
III	Other Income	28.45	19.28	16.34	67.81	85.85	108.37
IV	Total Income (I+II+III)	1,122.69	1,172.04	895.87	3,240.37	3,230.93	4,350.80
V	Expenses						
	a). Cost of materials consumed	-	-	-	-	6.08	6.08
	b). Purchase of Stock-in-Trade	-	-	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	d). Employee benefit expenses	233.69	221.76	199.02	678.32	582.86	787.61
	e). Finance costs	-	-	-	-	11.22	11.22
	f). Depreciation and amortization expense	174.41	180.67	180.46	535.18	539.59	717.27
	g). Other Expenses	334.24	379.77	323.33	1,049.98	989.28	1,378.39
	Total expenses	742.34	782.20	702.81	2,263.48	2,129.03	2,900.57
VI	Profit/(Loss) before exceptional items and tax (IV-V)	380.35	389.84	193.06	976.89	1,101.90	1,450.23
VII	Exceptional items	-	-	-	-	-	-
VIII	Profit/(Loss) before tax (VI-VII)	380.35	389.84	193.06	976.89	1,101.90	1,450.23
IX	Tax expense						
	a). Current Tax	-	-	-	-	-	-
	b). Deferred Tax	44.30	106.44	54.89	212.96	310.17	291.70
	Total Tax Expense (IX)	44.30	106.44	54.89	212.96	310.17	291.70
X	Profit/(Loss) for the period (VIII-IX)	336.05	283.40	138.17	763.93	791.73	1,158.53
XI	Other Comprehensive Income						
	a). Items that will not be reclassified to Profit or Loss						
	Re - measurement of the defined benefit obligations	1.12	1.11	1.40	3.35	4.20	4.47
	b). Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	Less: Income Tax	(0.10)	(0.35)	(0.35)	(0.73)	(1.06)	(1.12)
	Total Other Comprehensive Income (a+b)	1.02	0.76	1.05	2.62	3.14	3.35
XII	Total Comprehensive Income for the period (X+/-XI)	337.07	284.16	139.22	766.55	794.87	1,161.88
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e. Other equity						2,123.95
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)						
	a). Basic	0.55	0.46	0.23	1.25	1.30	1.90
	a) Diluted	0.55	0.46	0.23	1.25	1.30	1.90

See accompanying notes to the financial results

Notes:

1. The above financial results for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 29th January, 2024 and have undergone a 'limited review' by the Statutory Auditors of the Company.
2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June, 2022 and Long Form Standing certificate dated 15th June, 2022 respectively, received from the concerned authorities. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence no longer CFS is applicable.
5. The Company received winding up order for Zenotech Laboratories Nigeria Limited during FY: 2019-20. However, related filings with RBI is pending.
6. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
7. The Company has only one segment, i.e. Pharmaceuticals.
8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman
DIN-01219312

Place: Mumbai
Date: 29-January-2024